Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation

LUND, Sweden, March 26, 2019 /PRNewswire/ — Hansa Biopharma AB
(NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme
technology for rare IgG-mediated diseases, announced today that it
received Clinical Trial Application and Ethics Committee approvals
for the company’s Phase 2…

Source: FS – Machinery
Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation



Leave a Reply